TP-0903 is primarily investigated for its potential in cancer treatment. It functions as an inhibitor of AXL receptor tyrosine kinase, which is often overexpressed in various cancers and associated with tumor growth, metastasis, and drug resistance. By targeting AXL, TP-0903 aims to disrupt these processes, making it a promising candidate for therapies against aggressive cancers such as pancreatic, ovarian, and lung cancer. Additionally, it is being studied in combination with other anticancer agents to enhance therapeutic efficacy and overcome resistance mechanisms in tumors. Its application extends to preclinical and clinical trials, where it shows potential in improving patient outcomes in challenging cancer types.